百时美施贵宝admilparant三期ALOFT-IPF主要终点达标（60mg），同日另获RYZ101三期积极读数，盘前一度涨近6%

Bristol Myers Squibb (BMY) announced positive topline results from its pivotal Phase 3 ALOFT-IPF trial, with admilparant meeting the study's primary endpoint in adults with idiopathic pulmonary fibrosis.
The findings support the potential of the investigational therapy as a new treatment option for progressive lung disease.
Idiopathic pulmonary fibrosis (IPF) is a chronic and life-threatening lung disease in which scar tissue builds up in the lungs, making it increasingly difficult to breathe. The condition is associated with a steady decline in lung function, and currently available treatments can slow disease progression but do not stop or reverse it.
Admilparant is an investigational oral therapy designed to block the lysophosphatidic acid receptor 1 (LPA1) pathway, which is believed to play a role in the development and progression of pulmonary fibrosis.
The Phase 3 ALOFT-IPF study evaluated two dose levels of Admilparant, 60 mg and 120 mg taken twice daily for at least 52 weeks, compared with placebo. The trial enrolled approximately 1,255 adults with idiopathic pulmonary fibrosis.
The study met its primary endpoint at the 60 mg dose, with patients receiving admilparant demonstrating a statistically significant improvement in the change in forced vital capacity (FVC) from baseline at Week 52, a key measure of lung function, compared with placebo.
At the 120 mg dose, admilparant also slowed the decline in lung function, compared with placebo after 52 weeks of treatment.
At the 120 mg dose, admilparant also slowed the decline in lung function, although the result did not reach statistical significance.
According to the company, admilparant demonstrated a favorable safety and tolerability profile across both treatment groups. Discontinuations due to adverse events were low and were similar to those seen with placebo.
The Phase 3 findings build on earlier Phase 2 data in which admilparant reduced the rate of lung function decline compared with placebo in patients with pulmonary fibrosis.
Bristol Myers Squibb said it plans to complete a full evaluation of the Phase 3 data and engage with health authorities to support future regulatory submissions. Detailed results will be presented at a future medical meeting.
The company is also evaluating admilparant in the Phase 3 ALOFT-PPF study in patients with progressive pulmonary fibrosis, with topline results expected in early 2027.
BMY has traded between $42.52 and $68.64 over the past year. The stock closed Friday's trading at $59.12, down 0.77%. In pre-market trading, the stock is at $60.98, up 3.16%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.